The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Stanley Dudrick's Memorial Hospital

Status and phase: Terminated; Phase 4

Conditions: Short Bowel Syndrome

Treatments: Drug: Dipeptidyl peptidase-4 inhibitor

Study type: Interventional

Funder types: Other

Identifiers

NCT02653131

GLP-1

Details and patient eligibility

About

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Full description

The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Enrollment: 8 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months
• stable metabolic status
• benign disease

Exclusion criteria

• HPN < 12 months
• metabolically unstable
• cancer as the reason for intestinal failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 2 patient groups

DPP-4

Experimental group

Description:

The administration of the DPP-4 inhibitor in the form of a pill once per day

Treatment:

Drug: Dipeptidyl peptidase-4 inhibitor

NO DPP

No Intervention group

Description:

no therapy